Meeting
2019 ASCO Annual Meeting
Mutation and treatment profiles of patients with concurrent EGFR and ALK actionable mutations (muts).
Authors
Jun Zhao
Beijing University School of Oncology Beijing Institute for Cancer Research, Beijing, China
Jun Zhao , Caixia Liu , Hui Liu , Yong He Sr., Liqiang Rao , Jiqing Hao , Xiang Liu , Zefeng Xie , Rongrong Chen , Xuefeng Xia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3138)
DOI
10.1200/JCO.2019.37.15_suppl.3138
Abstract #
3138
Poster Bd #
130
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2011 ASCO Annual Meeting
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.
First Author: J. Yang
Poster
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
First Author: Melissa Lynne Johnson
Poster
2023 ASCO Annual Meeting
Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.
First Author: Xiuning Le